

1 **COVID-19 associated autoimmunity is a feature of severe respiratory disease - a Bayesian**
2 **analysis.**

3

4 Uriel Trahtemberg MD, PhD¹; Robert Rottapel MD^{2,3}; Claudia C dos Santos MD^{1,4,5}; Alex P Di
5 Battista, PhD^{4,6,7}; Arthur S. Slutsky, MD^{4,5}; Andrew J Baker MD^{1,4,5}; and Marvin J Fritzler MD,
6 PhD*⁸ on behalf of the COVID19 Longitudinal Biomarkers of Lung Injury (COLOBILI) study group.

7

8 1. Critical Care Department, St. Michael's Hospital, Toronto, ON, Canada.

9 2. Departments of Medicine and Immunology, University of Toronto, Toronto, ON, Canada.

10 3. Division of Rheumatology, St. Michael's Hospital, Toronto, ON, Canada.

11 4. Keenan Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael's
12 Hospital, Toronto, ON, Canada.

13 5. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON,
14 Canada

15 6. Faculty of Kinesiology & Physical Education, University of Toronto, Toronto ON, Canada.

16 7. Defence Research and Development Canada, Toronto Research Centre, Toronto, ON,
17 Canada.

18 8. Cumming School of Medicine, University of Calgary, Calgary, AB Canada.

19

20 * Corresponding author:

21 Marvin J. Fritzler PhD MD

22 Cumming School of Medicine

23 University of Calgary

24 3330 Hospital Dr. NW

25 Calgary, AB, Canada T2N 4N1

26 Email: fritzler@ucalgary.ca

27 Telephone: +01-403-220-3533

28

29 Abstract word count: 248

30 Manuscript word count: 2717

31 References: 22

32 Figures & Tables: 5

33 Supplemental Tables: 2

34 **Abstract**

35 **Background:** Serological and clinical features with similarities to systemic autoimmunity have
36 been reported in severe COVID-19, but there is a lack of studies that include contemporaneous
37 controls who do not have COVID-19.

38 **Methods:** Observational cohort study of adult patients admitted to an intensive care unit with
39 acute respiratory failure. Patients were divided into COVID⁺ and COVID⁻ based on SARS-CoV-2
40 PCR from nasopharyngeal swabs and/or endotracheal aspirates. No COVID-19 specific
41 interventions were given. The primary clinical outcome was death in the ICU within 3 months;
42 secondary outcomes included in-hospital death and disease severity measures. Measurements
43 including autoantibodies, were done longitudinally. ANOVA and Fisher's exact test were used
44 with $\alpha=0.05$, with a false discovery rate of $q=0.05$. Bayesian analysis was performed to provide
45 credible estimates of the possible states of nature compatible with our results.

46 **Results:** 22 COVID⁺ and 20 COVID⁻ patients were recruited, 69% males, median age 60.5 years.
47 Overall, 64% had anti-nuclear antibodies, 38% had antigen-specific autoantibodies, 31% had
48 myositis related autoantibodies, and 38% had high levels of anti-cytokine autoantibodies. There
49 were no statistically significant differences between COVID⁺ and COVID⁻ for any of the clinical or
50 autoantibody parameters. A specific pattern of anti-nuclear antibodies was associated with
51 worse clinical severity for both cohorts.

52 **Conclusions:** Severe COVID⁺ patients have similar humoral autoimmune features as comparably
53 ill COVID⁻ patients, suggesting that autoantibodies are a feature of critical illness regardless of
54 COVID-19 status. The clinical significance of autoimmune serology and the correlation with
55 severity in critical illness remains to be elucidated.

56

57 **Introduction**

58 The immune response in SARS-CoV2 infection shows evidence of immune dysregulation in
59 patients with severe clinical manifestations¹. While there is continued debate about the nature
60 of the heightened inflammatory responses in severe COVID-19 patients^{2,3} there is mounting
61 evidence that some clinical and serological features bear remarkable similarities to systemic
62 autoimmune conditions⁴⁻⁶. In addition, some COVID-19 patients continue to develop *de novo*
63 clinical signs and symptoms reminiscent of autoimmune diseases during convalescence⁷.
64 Potential mechanisms leading to autoimmunity in COVID-19 include increased release of self-
65 antigens as a result of tissue damage, neutrophil activation and NETosis⁸, molecular mimicry
66 from homologous sequences of SARS-COV2 with human proteins⁹ and activation of autoreactive
67 immune cells due to cytokinemia³.

68

69 A significant limitation of studies that have reported the emergence of autoantibodies (AAB) in
70 COVID-19^{4, 6, 10} has been the lack of control groups with similar clinical characteristics and the
71 lack of longitudinal data monitoring the development of autoimmunity over time. Our study
72 provides evidence that, when observed longitudinally, severe COVID-19 patients have similar
73 AAB prevalence as a control cohort of critically ill patients.

74

75 **Methods**

76 **Study design.** This report is part of the COLOBILI study – Coronavirus Longitudinal Biomarkers in
77 Lung Injury, an observational cohort study that includes analysis of biological samples conducted
78 at St. Michael’s Hospital (Toronto, ON, Canada). The study was approved by the Research Ethics
79 Board of St. Michael’s Hospital (REB# 20-078). Informed consent was obtained from the patients
80 or their legal representatives. In cases where it was not possible to obtain consent, patients

81 were enrolled using a deferred consent model and kept in the study until they regained
82 capacity, or a surrogate decision maker was identified.

83 The inclusion criteria were all patients above age 18 years admitted to the Medical-Surgical or
84 Trauma-Neuro intensive care units (ICU) with acute respiratory distress, suspected to have
85 COVID-19. The exclusion criteria were refusal to participate, inability to ascertain mortality
86 status during the first 2 weeks of the study, failure to obtain a blood sample on either day 0 or 1,
87 or individuals known to have had COVID-19 in the 4 weeks prior to admission in any setting.

88 Patients were followed for up to 3 months if they were in hospital or until hospital discharge,
89 whichever occurred first. The primary outcome was death in the ICU; secondary outcomes
90 included death outside the ICU, ICU utilization metrics, and organ dysfunction measures and
91 scores (see Table 1). COVID19 status of all patients was determined according to diagnostic PCR
92 of nasopharyngeal swabs and/or endotracheal aspirates. Further PCR tests were repeated by
93 the clinical and infection control teams at their discretion to confirm negativity or if there was
94 suspicion of a false negative result based on clinical observations. All patients in the PCR
95 negative cohort had at least two negative tests performed acutely. One patient had only one
96 test done acutely.

97 The study started on March 26th, 2020, and the first patient was recruited on March 29th, 2020.
98 The study is ongoing; the last patient from the cohort in this manuscript was recruited on May
99 17th, 2020, and the data was censored for analysis on May 31st, 2020. No specific COVID-19
100 therapeutic interventions were administered as these patients were treated prior to the
101 availability of evidence-based treatment guidelines demonstrating effective therapies. Patients
102 in the study cohort were separated into COVID-19 positive (COVID⁺) and non-COVID-19 (COVID⁻)
103 based on the RT-PCR results.

104 **Data and sample collection.** Demographics, clinical data and clinical laboratory results were
105 collected from the patients' paper and electronic medical records. Blood samples were collected
106 longitudinally starting immediately upon admission if possible (defined as day 0), and on the
107 morning of days 1, 3, 5, 7 and 10; after day 10 or ICU discharge, they were sampled every 2
108 weeks. Clinical data were obtained at the same times even if blood samples were unavailable.
109 Blood samples were collected, handled and processed in rigorous standard operating procedure
110 in a dedicated translational research station located inside the ICU (see online materials for
111 details). To analyze longitudinal trends, only patients with 3 or more sequential samples were
112 included in the study. To mitigate bias, five patients with shorter ICU admissions were included;
113 2 had early deaths and 3 had early discharges.

114 **Experimental procedures.** All autoantibody and serology assays were performed by Mitogen
115 Diagnostics Laboratory (MitogenDx, Calgary, AB, Canada). A HEp-2 indirect immunofluorescence
116 assay (IFA) was used to detect anti-cellular antibodies (referred to as anti-nuclear antibodies
117 (ANA); NOVA Lite HEp-2, Inova Diagnostics, San Diego, CA) and images read and archived on an
118 automated instrument (Nova View, Inova Diagnostics).

119 All samples were tested for systemic autoimmune disease-related AAB by a FIDIS Connective13
120 addressable laser bead immunoassay (TheraDiag, Paris, France) and read on a Luminex 200
121 system using the MLX-Booster software. Anti-dsDNA positivity and titers were detected by a
122 chemiluminescence test (Bio Flash®, Inova Diagnostics, San Diego, USA).

123 All samples were also tested for AAB associated with autoimmune inflammatory myopathies
124 using a multiplexed solid-phase line immunoassay (Euroimmun AG, Luebeck, Germany), and
125 anti-NT5c1A by addressable laser bead immunoassay. Anti-Cytokine antibodies were assayed
126 using a multiplexed addressable laser bead immunoassay (Millipore, Oakville, ON, Canada;
127 HCYTAAB-17K-15) on a Luminex 200 system.

128 **Nomenclature.** AAB is a general term that encompasses the autoimmune humoral responses
129 assayed. The HEp-2 IFA are commonly referred as anti-nuclear antibodies (ANA) even though
130 cytoplasmic and cell cycle patterns were included in the analysis. Their classification was
131 according to the International Consensus on Autoantibody Patterns (ICAP) nomenclature
132 (www.anapatterns.org: last accessed 1/29/2021). The AAB test results that identified specific,
133 named target antigens (see details above), were called collectively specific AAB (spAAB). We
134 have further separated them into myositis-related and non-myositis-related AAB. Anti-cytokine
135 AAB are referred to directly.

136 **Data analysis.** All the data was organized by UT and analyzed by UT and ADB. ANOVA was used
137 for continuous variables and Fisher's exact test was used for categorical variables at $\alpha=0.05$,
138 adjusted for multiple comparisons as indicated in the text using the false discovery rate at
139 $q=0.05$. Bayesian analysis: a Gibbs Markov chain Monte Carlo sampling was employed to
140 estimate posterior distributions of the difference between COVID⁺ and COVID⁻, using non-
141 informative priors. The mean difference and 95% high density intervals (HDI) were calculated. A
142 result was considered significant for a given variable if the 95% HDI of the difference between
143 COVID⁺ vs. COVID⁻ patients did not enclose zero. An exploratory analysis was conducted to
144 estimate the effect different priors would have on the posterior distributions; the priors
145 represent varying pre-existing assumptions on the prevalence of differences between COVID⁺ vs.
146 COVID⁻ patients. All statistical and graphical analyses were performed on R (RStudio, version
147 1.3.1093, Boston, United States) and JMP Pro (version 15.2.1; SAS Institute Inc, Cary, NC, USA).

148 **Online methods.** For additional details, see the online methods.

149

150 **Results**

151 The demographic and clinical characteristics, including past medical history are shown in Table 1
152 (see also Table S1). No statistically significant clinical differences were noted between the two
153 patient groups. Importantly, both patient groups experienced comparable disease severity^{11, 12}
154 as measured in ICU days, mechanical ventilation days and mortality rates, as well as surrogate
155 severity scores (Table 1). Age, sex and ethnicity were not correlated with the presence of AAB
156 (not shown).

157

158 The presence of ANA in general were not significantly associated with disease severity (Figure
159 1a), although there was a positive correlation with disease severity that did not reach statistical
160 significance. Nevertheless, the presence of ICAP AC19 (cytoplasmic dense fine speckled) and/or
161 AC20 (cytoplasmic fine speckled) IFA patterns, specifically, were consistently associated with
162 worse severity of illness scores in both patient groups (Figure 1a). Neither the prevalence nor
163 the IFA staining patterns were different between the COVID⁺ and COVID⁻ groups, although some
164 patients demonstrated unique IFA patterns (Figure 1b).

165

166 We compared the incidence of spAAB directed against autoantigens typically associated with
167 systemic autoimmune diseases and myositis in critically ill COVID⁺ and COVID⁻ patients (Figure
168 2). Patients who had a single, transient, low-titer spAAB result were not classified as having a
169 positive test. Figure 2 shows that the presence of spAAB was similar in both COVID⁺ and COVID⁻.
170 In addition, there was no difference between the temporal development of spAAB between the
171 two groups (Figure 2), nor was there a correlation between the emergence of AAB and SARS-
172 CoV-2 seroconversion in the COVID⁺ group (not shown). Of note, most of these AAB persisted
173 beyond 10 days (Figure 2), with the longest measurement available up to 54 days of

174 hospitalization. There was no correlation between spAAB with COVID-19 status (Table 1) or any
175 of the measures of disease severity.

176

177 50% of COVID⁺ patients had high titers of anti-cytokine AAB, as compared to 25% for COVID⁻
178 (Table 2). This difference was driven mainly by anti-interleukin (IL)-6, anti-IL-10 and anti-IL-17f
179 AAB but it did not reach statistical significance (Tables 1 and 2). When analyzing all positive
180 results of anti-cytokine AAB (as opposed to only the high titres), the difference between COVID⁺
181 and COVID⁻ remained at ~25% (Table 1). Interestingly, COVID⁻ patients had a similar incidence of
182 anti-interferon- γ and anti-interferon- β AAB as COVID⁺ (Table 2). Anti-cytokine AAB were not
183 associated with the presence of spAAB or ANA (not shown).

184

185 To better understand the ramifications of our data as well as confirm our results, we performed
186 a Bayesian analysis, which is more information-rich than null hypothesis statistical testing
187 (NHST)¹³. In Figure 3a we show the distribution of posterior probabilities for the difference
188 between the COVID⁺ and COVID⁻ cohorts for ANA, spAAB and anti-cytokine AAB. Since all the
189 95% credible HDI cross the zero, our data is compatible with the null hypothesis, confirming the
190 results from the NHST analysis. Importantly, this analysis used a non-informative prior; that is,
191 we did not assume any previous knowledge of what the true state of nature is. This is fitting
192 since there little is known on the prevalence of autoimmune phenomena among critically ill
193 patients⁵ and, to our knowledge, this is the first report on autoimmunity among severe COVID-
194 19 patients that has a control group of similarly ill, critical patients. We then performed an
195 exploratory analysis assigning speculated, *a priori* differences between the COVID⁺ and COVID⁻
196 populations – Bayesian prior probabilities. Figure 3b shows that, for our results to be compatible
197 with the existence of a significant difference, it would be necessary to assume a prior probability

198 of the COVID⁺ patients having a prevalence that is at least 15% higher for anti-cytokine AAB, 20%
199 higher for spAAB, and 35% higher for ANA. The resulting posterior mean differences would be in
200 the order of 15 to 20% more autoimmunity among COVID⁺ than COVID⁻ (summarized in Table
201 S2).

202

203 **Discussion**

204 We analyzed disease severity and presence of AAB in 22 COVID⁺ and 20 COVID⁻ ICU patients with
205 respiratory distress of similar severity, enrolled contemporaneously, over time. We used HEp2
206 IFA to typify ANAs, as well as solid-phase multi-analyte arrays and bead-based multiplexed
207 immunoassays to typify specific autoreactive antigens such as those observed in autoimmune
208 diseases such as systemic lupus erythematosus, Sjögren syndrome, systemic sclerosis,
209 autoimmune inflammatory myopathies, and others⁴⁻⁶.

210 Overall, close to 15,000 data points were collected between demographic variables and
211 laboratory and clinical variables over time. We observed high prevalence and titres of AAB
212 among the COVID⁺ patients our study (68% had ANA), in agreement with some previous reports
213 of COVID^{+14, 15}. Yet, surprisingly, we also observed high prevalence and titres of AAB in the
214 COVID⁻ patient cohort (60% had ANA). In another cross-sectional study⁴, the majority of positive
215 sera had reactivity to only single nuclear antigens, whereas most of our patients showed
216 multiple reactivities (Figure 2), suggesting a relatively widespread loss of humoral tolerance in
217 some of our patients. We found no major differences in either the autoantigen specificity,
218 temporal dynamics, or titers in COVID⁺ vs. COVID⁻ cohorts. These data suggest that AAB
219 production may be a feature of immune dysfunction associated with acute systemic illness
220 rather than specifically with a SARS-CoV-2 driven immune pathology. Importantly, specific ANA
221 patterns (AC19 and/or AC20) were broadly correlated with disease severity measures,

222 suggesting a causal relationship, or at least a common factor “driving” autoreactive B cell
223 responses in critically ill patients.
224
225 A previous study reported that approximately 10% of patients with life-threatening COVID-19
226 pneumonia had neutralizing IgG AAB against a spectrum of interferon proteins, which blocked
227 SARS-CoV-2 infection *in vitro*¹⁶. Of note, these AAB were not found in asymptomatic or mild
228 SARS-CoV-2 infection, but they were not studied in similarly ill, COVID- patients. Our results
229 show that matched COVID⁻ controls have a similar incidence of anti-interferon- γ and anti-
230 interferon- β AAB as COVID⁺ patients. While we did not study if the anti-cytokine AAB in our
231 study had neutralizing activity, we did not find that the presence of these AAB differed between
232 COVID⁺ and COVID⁻. The small sample size and the large absolute difference for anti-IL-6, anti-IL-
233 10 and anti-IL-17f raise the possibility of a type-2 error. We addressed this concern using
234 Bayesian analysis, which confirmed the results of the NHST.
235
236 Our data and analysis support that, humoral autoimmunity, as described in detail using an
237 extensive panel of ANA, spAAB and anti-cytokine AAB, longitudinally, does not seem to be a
238 particular characteristic of COVID⁺ patients but rather of critically ill patients with respiratory
239 failure. The collection of data over time significantly increases the reliability of our results by a)
240 reducing the biases of different, arbitrary sampling times between different patients, b)
241 providing test-retest internal validity, and c) characterizing the development of autoimmunity in
242 a physiological context - over time. Although there is no direct evidence to assume *a priori* that
243 COVID⁺ have more autoimmunity than COVID⁻, some clinicians may consider the immune
244 characteristics of severe COVID-19 enough reason to warrant such assumptions. Our analysis
245 suggests that, in that case, the expected differences would be in the order of a modest 15-20%

246 (Figure 3b, Table S2). These results provide boundaries to the autoimmunity phenomenon of
247 COVID⁺ patients and provide the context of high prevalence of autoimmunity among critically ill
248 patients with respiratory failure in general. Nevertheless, there are some suggestions in our data
249 that, within this context, COVID-19 patients may have a tendency for particular autoimmune
250 phenotypes, as hinted by the large absolute difference of anti-IL6, anti-IL10 and anti-IL17f AAB.
251 Larger studies are needed to assess this possibility, as well as the pathogenic role of AAB in both
252 COVID⁺ and COVID⁻ patients, which is yet to be demonstrated.

253

254 Given that all of our patients (both COVID⁺ and COVID⁻) had respiratory failure, it may be that
255 the association between AAB production is related to lung injury and/or lung endothelial
256 pathology, a known feature of acute lung injury¹⁷ regardless of etiology. The activation of both
257 innate immune and adaptive responses to abnormal danger-associated molecular patterns
258 released into the circulation following the initial lung injury may contribute to the loss of
259 humoral tolerance¹⁸⁻²¹. Another potential cause of AAB formation may be related to immune
260 activation associated with the bio-trauma of ventilator associated lung injury, in the context of
261 loss of pulmonary compartmentalization²². This could explain some of the AAB that developed
262 during the course of hospitalization (figure 2). Indeed, perhaps the most salient result of our
263 study is the high prevalence of broad autoimmune serology among the critically ill, a
264 phenomenon we describe for the first time here. These results stand in stark contrast to the
265 known prevalence in the general population of about 5%, bearing further study.

266

267 Our study's main shortcoming is the small sample size. We account for this by employing
268 Bayesian analysis to explore the boundaries of the possible states of nature underlying our
269 results. Another shortcoming is the need to consolidate the different autoimmune serologies

270 under the broad categories of ANA, spAAB and anti-cytokine AAB, due to the small sample size
271 and to avoid multiple testing. Nonetheless, we do present these results in detail, providing a
272 qualitative assessment, and performed analyses of specific features when the sample size
273 allowed for it, such as for the AC19 and/or AC20 patterns, or the ANA titres.

274

275 In conclusion, in some patients, severe COVID-19 is characterized by immune dysregulation with
276 clinical features of systemic autoimmunity. We present evidence that humoral autoimmunity is
277 a common feature of critically ill patients with respiratory deterioration. Our study urges caution
278 in the interpretation of AAB test results among COVID⁺ patients. Further studies are needed to
279 determine whether transient or sustained production of AAB in the setting of acute illness is
280 associated with the development of systemic autoimmunity.

281

282 **Declarations**

283 **Ethics approval and consent to participate**

- 284 • This research was approved by Research Ethics Boards at St Michael's Hospital and
285 performed in accordance with the Helsinki Declaration of 1975 as revised in 2013.

286 **Availability of data and materials**

- 287 • The datasets used and/or analysed during the current study are available from the
288 corresponding author on reasonable request.

289 **Competing interests**

- 290 • MJF is the Director of MitogenDx. MJF is a consultant for and received speaking
291 honoraria from Inova Diagnostics Inc (San Diego, CA) and Werfen International
292 (Barcelona, Spain). All the other authors have no disclosures to declare.

293 **Funding**

- 294 • St Michael's Hospital Foundation, internal competitive grant to AB and CDS.
295 • Autoantibody testing was provided as a gift in kind by MitogenDx (Calgary, AB, Canada)

296 **Authors' contributions**

- 297 • This report is part of the COLOBILI study (Coronavirus longitudinal biomarkers in lung
298 injury). AB and CDS are principal investigators; MJF, RR and AS are collaborators/co-
299 investigators and UT is the research lead.
- 300 • RR, MJF, UT, and CDS conceived of the study; MJF, UT and RR wrote the manuscript
301 drafts; AS, AB and CDS provided critique and technical guidance; UT and ADB performed
302 the data analysis and creation of the figures. All authors edited the manuscript, through
303 to the final version, read and approved the final submission.

304 **Acknowledgements**

305 • The authors acknowledge the technical assistance of Haiyan Hou, Meifeng Zhang and
306 Emily Walker in the MitogenDx Laboratory at the University of Calgary. We thank
307 Marlene Santos, Gyan Sadhu, Imrana Khalid, and Sebastian Duncan, the research
308 coordinators at St Michael’s Hospital Critical Care Research Unit. We are grateful to
309 patients and families that have generously consented to the study.

310 **Study registration**

311 • NCT04747782 – clinicaltrials.gov

312

313 **References**

- 314 1. Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-
315 19. *Nat Rev Immunol* 2020;20:581-582.
- 316 2. Fajgenbaum DC, June CH. Cytokine Storm. *N Engl J Med* 2020;383:2255-2273.
- 317 3. Leisman DE, Ronner L, Pinotti R et al. Cytokine elevation in severe and critical COVID-19: a
318 rapid systematic review, meta-analysis, and comparison with other inflammatory
319 syndromes. *Lancet Respir Med* 2020;8:1233-1244.
- 320 4. Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of
321 Autoantibody Responses in Acute Coronavirus Disease 2019 (COVID-19). *J Transl*
322 *Autoimmun* 2020;3:100073.-doi: 10.1016/j.jtauto.2020.100073.
- 323 5. Gao ZW, Zhang HZ, Liu C, Dong K. Autoantibodies in COVID-19: frequency and function.
324 *Autoimmun Rev* 2021; Epub ahead of print. Jan 18:-doi: 10.1016/j.autrev.2021.102754.
- 325 6. Sacchi MC, Tamiazzo S, Stobbione P et al. SARS-CoV-2 Infection as a trigger of
326 autoimmune response. *Clin Transl Sci* 2020;Online ahead of print. Dec 11:-doi:
327 10.1111/cts.12953.
- 328 7. Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. *Autoimmun Rev*
329 2020;19:102695.
- 330 8. Vorobjeva NV, Chernyak BV. NETosis: Molecular Mechanisms, Role in Physiology and
331 Pathology. *Biochemistry (Mosc)* 2020;85:1178-1190.
- 332 9. Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and
333 mammalian proteomes: implications for the vaccine. *Immunol Res* 2020;68:310-313.
- 334 10. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. *Curr Opin Rheumatol*
335 2020;33(2):155-162. doi: 10.1097/BOR.0000000000000776.

- 336 11. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation
337 and Treatment. *Postgrad Med J* 2020; [Epub ahead of print]:-doi: 10.1136/postgradmedj-
338 2020-138577.
- 339 12. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-
340 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
341 *Lancet Respir Med* 2020;Epub ahead of print.
- 342 13. Haidar MA, Jourdi H, Haj HZ et al. Neurological and Neuropsychological Changes
343 Associated with SARS-CoV-2 Infection: New Observations, New Mechanisms.
344 *Neuroscientist* 2021;1073858420984106.
- 345 14. Vlachoyiannopoulos PG, Magira E, Alexopoulos H et al. Autoantibodies related to systemic
346 autoimmune rheumatic diseases in severely ill patients with COVID-19. *Ann Rheum Dis*
347 2020;79:1661-1663.
- 348 15. Pascolini S, Vannini A, Deleonardi G et al. COVID-19 and immunological dysregulation: can
349 autoantibodies be useful? *Clin Transl Sci* 2020.
- 350 16. Bastard P, Rosen LB, Zhang Q et al. Auto-antibodies against type I IFNs in patients with
351 life-threatening COVID-19. *Science* 2020;370:eabd4585-doi: 10.1126/science.abd4585.
- 352 17. Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary Vascular Endothelialitis,
353 Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med* 2020;383:120-128.
- 354 18. Han S, Mallampalli RK. The acute respiratory distress syndrome: from mechanism to
355 translation. *J Immunol* 2015;194:855-860.
- 356 19. Sivapalan P, Bonnesen B, Jensen JU. Novel Perspectives Regarding the Pathology,
357 Inflammation, and Biomarkers of Acute Respiratory Distress Syndrome. *Int J Mol Sci*
358 2020;22:205.

- 359 20. Kumar V. Pulmonary Innate Immune Response Determines the Outcome of Inflammation
360 During Pneumonia and Sepsis-Associated Acute Lung Injury. *Front Immunol* 2020;11:1722-
361 doi: 10.3389/fimmu.2020.01722.
- 362 21. Lin S, Wu H, Wang C, Xiao Z, Xu F. Regulatory T Cells and Acute Lung Injury: Cytokines,
363 Uncontrolled Inflammation, and Therapeutic Implications. *Front Immunol* 2018;9:1545-
364 doi: 10.3389/fimmu.2018.01545.
- 365 22. Dos Santos CC, Slutsky AS. The contribution of biophysical lung injury to the development
366 of biotrauma. *Annu Rev Physiol* 2006;68:585-618. doi:
367 10.1146/annurev.physiol.68.072304.113443.
- 368
- 369
- 370

371 **Figure Legends**

372 **Figure 1: Anti-nuclear antibodies**

373 A) Association between anti-nuclear antibodies and outcomes. Refer to the legend of Table 1 for
374 details on the variables. AC19 is shown together with AC20 given their similarity, as is the
375 common usage. The variables were compared in a pairwise fashion using ANOVA for continuous
376 variables and Fisher's exact test for categorical variables at $\alpha=0.05$, followed by the false
377 discovery rate at $q=0.05$; green squares indicate lack of association, red squares indicate
378 statistically significant associations. Y/N denotes dichotomization into whether they were
379 present "yes or no" (i.e. titre above 1:80). Similar to table 1, the ANA represent the results
380 during longitudinal sampling up to day 10 of ICU admission, for standardization among patients.
381 The clinical outcomes were measured for up to 3 months. B) Characterization of autoantibodies.
382 Heatmap representation of the highest ANA titers during the first 3 months of admission.
383 Includes more patients than in Table 1 and Figure 1a since some AABs developed after 10 days.
384 This may introduce bias since not all patients had prolonged hospitalizations but is a better
385 representation of the dynamics and spectrum of ANA detected. Only patients with titers > 1:80
386 are included. AC4 is shown together with AC5, and AC19 is shown together with AC20, given
387 their similarity, as is the common usage. AC7, 26, 27 and 28 are shown together given their
388 rarity individually.

389

390 **Figure 2: Evolution of specific autoantibody serology and titres over time**

391 The left panel shows the specific AAB serology of COVID+ patients, the right panel shows the
392 specific AAB serology of COVID- patients, and the lower panel shows specific AAB that were
393 detected on only one patient, shown separately for clarity. The titres were classified into low,
394 medium and high levels using cutoffs established by the laboratory, shown in light grey, dark

395 grey and black, respectively; white indicates negative. Arrival indicates the first sample
396 obtained, either on the day of admission or the next morning. Within 10 d indicates during the
397 longitudinal sampling, up to day 10 of ICU stay. After 10 d indicates later samples, collected
398 every two weeks; not all patients had samples after 10 days. The following specific AAB were not
399 detected in any samples: histones, Sm/U2-U6 RNP, U1-RNP, ribosomal P, topoisomerase I, Mi2-
400 α , MDA5, NXP2, PL7, PL12, SRP, EJ, OJ, HMGCR or NT5C1 A/Mup44 and SAR1.

401

402 Figure 3: Bayesian analysis of the 95% high density credible interval of the difference between
403 COVID⁺ and COVID⁻ levels of autoimmune serology

404 A) Posterior distributions of the difference in humoral autoimmunity in COVID⁺ vs. COVID⁻
405 patients. The histograms plot the difference between the COVID⁺ and COVID⁻ in the proportion
406 of patients who are positive for the variables presented. The 95%HDI is visually represented by
407 the bold black line along the x-axis. The histograms represent simulations using four Gibbs
408 sampling chains employing a flat prior probability, at 5000 iterations per chain, minus 1% burn-
409 in, resulting in 19800 iterations in total for each histogram. B) Effect of prior bias on posterior
410 distributions. The data was generated using the same procedure as in "A", with the X axis
411 representing the difference in the posterior distribution between the COVID⁺ and COVID⁻. The
412 flat prior probability was exchanged varying levels of prior bias; the box and whiskers represent
413 the 95% HDI at each level of prior bias. The positive Y axes show the results assuming that
414 COVID⁺ have a higher incidence of positivity than COVID⁻, while the negative Y axes show the
415 opposite; the zero Y indicates a prior that assumes no bias, with an equal probability of 50%
416 positivity rate for both COVID⁺ and COVID⁻. A 95% HDI that does not include the zero on the X
417 axis indicates a significant difference between the COVID⁺ and COVID⁻ posterior probability

418 distributions at that level of prior bias, indicated with a red dot. The simulations were performed

419 on 5% intervals; the results are shown for 10% intervals for clarity.

420

421

422 Table 1: Patient Demographic, Clinical and Autoantibody Status

	Cohort	All	COVID⁺	COVID⁻
	<i>N</i>	42	22	20
Age	<i>Mean (CI)</i>	58.2 (62.7-54.1)	60.9 (66.6-55.3)	55.7 (62-48.7)
Sex	<i>N male (%)</i>	29/42 (69%)	17/22 (77%)	12/20 (60%)
Censored?	<i>N (%)</i>	5/42 (12%)	4/22 (18%)	1/20 (5%)
Number of days before censoring	<i>Mean (CI)</i>	39.4 (59.4-19.4)	44.3 (66.2-22.3)	20 (NA)
Days from symptom onset to ICU	<i>Mean (CI)</i>	6 (8.3-3.7)	7.5 (9.9-5.2)	4.2 (8.5-0)
APACHE II on ICU admission	<i>mean (CI)</i>	25.3 (27.6-22.9)	23.7 (27-20.4)	27 (30.5-23.5)
Mean of SOFA score for 1st 3 days	<i>mean (CI)</i>	9.6 (10.7-8.5)	9.3 (11-7.7)	9.9 (11.6-8.3)
Mean of SOFA score for 1st 7 days	<i>mean (CI)</i>	8.9 (10.1-7.8)	9.1 (11-7.3)	8.7 (10.3-7.2)
ICU days (censored)	<i>mean (CI)</i>	14.1 (17.3-10.8)	14.2 (20.5-7.8)	14 (16.9-11.1)
Death in ICU	<i>N (%)</i>	13/42 (31%)	7/22 (32%)	6/20 (30%)
Mechanical ventilation days (censored)	<i>Mean (CI)</i>	14.4 (18.9-10)	16.8 (25.1-8.6)	11.8 (14.9-8.7)
Total days of ventilation rescue measures	<i>Mean (CI)</i>	2.9 (4.3-1.4)	4.4 (7-1.8)	1.2 (2-0.4)
ANA (admission and up to 10d)	<i>N (%)</i>	27/42 (64%)	15/22 (68%)	12/20 (60%)
ANA titre?	<i>N (%) 0 to 80</i>	15/42 (36%)	7/22 (32%)	8/20 (40%)
	<i>N (%) 160 to 320</i>	16/42 (38%)	9/22 (41%)	7/20 (35%)
	<i>N (%) >320</i>	11/42 (26%)	6/22 (27%)	5/20 (25%)
Highest ANA titre	<i>mean (CI)</i>	655 (888-422)	677 (1021-334)	629 (986-273)
AC4 and/or AC5 pattern	<i>N (%)</i>	26/42 (62%)	13/22 (59%)	13/20 (65%)
AC19 and/or AC20 pattern	<i>N (%)</i>	15/42 (36%)	10/22 (45%)	5/20 (25%)
spAAB	<i>N (%)</i>	16/42 (38%)	9/22 (41%)	7/20 (35%)

Myositis-related spAAB	<i>N (%)</i>	13/42 (31%)	6/22 (27%)	7/20 (35%)
Ever high-positive anti-cytokine AAB?	<i>N (%)</i>	16/42 (38%)	11/22 (50%)	5/20 (25%)
Ever positive anti-cytokine AAB?	<i>N (%)</i>	22/42 (52%)	14/22 (64%)	8/20 (40%)

423 Abbreviations: AC, International Consensus on Autoantibody Patterns anti-cellular pattern
424 nomenclature; ANA, anti-nuclear antibodies; APACHE, Acute Physiology and Chronic Health
425 Evaluation (score); CI, 95% confidence interval; ICU, intensive care unit; IQR, 25—75%
426 interquartile length; SOFA, sequential organ failure assessment; spAAB, antigen-specific
427 autoantibodies. For more details on the nomenclature used for the autoimmune assays please
428 refer to the online materials and methods.

429 Legend: The data was censored on May 31st. Days from symptom onset were self-reported by
430 the patients or their representatives. ANA were determined with immunofluorescence using
431 Hep-2 cells and classified using the International Consensus on Autoantibody Patterns system.
432 The table reports the highest value found during longitudinal sampling up to day 10 of ICU
433 admission, for standardization among patients. Titres of 0 to 80 are considered negative and
434 titres above 320 are considered high. The SOFA score was performed daily for all patients; the
435 average was calculated for the first 3 and 7 days in the ICU for each patient, and the mean of
436 those averages are reported. For patients that underwent tracheostomy, mechanical ventilation
437 days are counted until successfully weaned from ventilatory support for 24 hrs. Rescue
438 measures included use of paralytics, proning and NO (counted additively if more than one
439 intervention used in the same day). The clinical outcomes were measured for up to 3 months.
440 There was no statistically significant difference between COVID⁺ and COVID⁻ patients for all
441 variables, using ANOVA for continuous variables and Fisher's exact test for categorical variables
442 at $\alpha=0.05$, followed by the false discovery rate at $q=0.05$.

443

444 Table 2 – High titre anti-Cytokine autoantibodies

Ever high positive	Cohort	All	COVID⁺	COVID⁻
	N	42	22	20
ALL	<i>N (%)</i>	16/42 (38%)	11/22 (50%)	5/20 (25%)
anti-GMCSF	<i>N (%)</i>	1/42 (2%)	1/22 (5%)	0/20 (0%)
anti-IFN- γ	<i>N (%)</i>	7/42 (17%)	3/22 (14%)	4/20 (20%)
anti-IL-1a	<i>N (%)</i>	1/42 (2%)	1/22 (5%)	0/20 (0%)
anti-IL-6	<i>N (%)</i>	5/42 (12%)	4/22 (18%)	1/20 (5%)
anti-IL-10	<i>N (%)</i>	5/42 (12%)	4/22 (18%)	1/20 (5%)
anti-IL-12p40	<i>N (%)</i>	2/42 (5%)	1/22 (5%)	1/20 (5%)
anti-IL-17a	<i>N (%)</i>	2/42 (5%)	2/22 (9%)	0/20 (0%)
anti-IL-17f	<i>N (%)</i>	4/42 (10%)	4/22 (18%)	0/20 (0%)
anti-IL-22	<i>N (%)</i>	1/42 (2%)	0/22 (0%)	1/20 (5%)

445 Abbreviations: GMCSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL,
446 interleukin.

447 Legend: The table reports the number of patients with high titres of anti-cytokine antibodies at
448 any time during the first 10 days of ICU admission. “ALL” represents all patient having a high
449 titre of anti-cytokine antibody of any type during that period. The numbers of the specific anti-
450 cytokine antibodies sum to more than “ALL” since some patients had more than one high titre
451 anti-cytokine antibody. Once adjusted for multiple comparisons, there were no statistically
452 significant differences between COVID+ and COVID- for any of the results (Fisher’s exact test at
453 $\alpha=0.05$ followed by the false discovery rate at $q=0.05$). The following anti-cytokine AAB did not

454 show high levels in any of the patients: anti-BAFF, anti-IFN- β , anti-TNF- α , anti-IL8, anti-IL-15 and

455 anti-IL-18.

456

Figure 1: Anti-nuclear antibodies

Figure 1a: Association between anti-nuclear antibodies and outcomes

	APACHE II	Rescue days	MV days	ICU days	ICU death	SOFA 3d	SOFA 7d
ANA Y/N							
ANA titre							
AC19 and/or AC20 Y/N							

Figure 1b: Characterization of autoantibodies


COVID-								COVID+									
StudyID	Max(AC1)	Max(AC3)	Max(AC10)	Max(AC21)	Max(AC24)	Max(AC4/5)	Max(AC19/20)	Max(AC7/26/27/28)	StudyID	Max(AC1)	Max(AC3)	Max(AC10)	Max(AC21)	Max(AC24)	Max(AC4/5)	Max(AC19/20)	Max(AC7/26/27/28)
4						640	160		1		2560				1280	2560	
8						320			2			160			160	160	
9			160			160		320	5						160		
13	320				640			2560	6							160	
16						160			7			160		320			1280
19			1280	320		640	320		10		160			160	160	160	
24						320			18		160						
36						640			20					640	160		
37					160	160			34					160			
41						160	160		39			160	1280	640			
48						320			44	160							
49					320				50			160	640	160			
55						640	320		52				1280	1280			
60	160		320			1280			53		640						640
63					320	320	160		54					640	320	160	
									56					160			
									59		160			1280	320		

Abbreviations: ANA, anti-nuclear antibodies; AC, International Consensus on Autoantibody Patterns anti-cellular pattern nomenclature; APACHE, Acute Physiology and Chronic Health Evaluation (score); Max, end point titer; ICU, intensive care unit; MV, mechanical ventilation; SOFA, sequential organ failure assessment (score). For more details on the nomenclature used for the autoimmune assays please refer to the online materials and methods.

Legend: A) Association between anti-nuclear antibodies and outcomes. Refer to the legend of Table 1 for details on the variables. AC19 is shown together with AC20 given their similarity, as is the common usage. The variables were compared in a pairwise fashion using ANOVA for continuous variables and Fisher’s exact test for categorical variables at $\alpha=0.05$, followed by the false discovery rate at $q=0.05$;

green squares indicate lack of association, red squares indicate statistically significant associations. Y/N denotes dichotomization into whether they were present “yes or no” (i.e. titre above 1:80). Similar to table 1, the ANA represent the results during longitudinal sampling up to day 10 of ICU admission, for standardization among patients. The clinical outcomes were measured for up to 3 months. B) Characterization of autoantibodies. Heatmap representation of the highest ANA titers during the first 3 months of admission. Includes more patients than in Table 1 and Figure 1a since some AABs developed after 10 days. This may introduce bias since not all patients had prolonged hospitalizations but is a better representation of the dynamics and spectrum of ANA detected. Only patients with titers > 1:80 are included. AC4 is shown together with AC5, and AC19 is shown together with AC20, given their similarity, as is the common usage. AC7, 26, 27 and 28 are shown together given their rarity individually.


Figure 2: Evolution of specific autoantibody serology and titres over time.



Abbreviations: AAB, autoantibodies; CENP-B, centromere protein; dsDNA, double stranded DNA; Jo-1, histidyl tRNA synthetase; Ku, a component of the DNA-dependent protein kinase complex; Mi2β, a component of the nucleosome remodeling-deacetylase complex; MDA, melanoma differentiating antigen 1; PCNA, proliferating cell nuclear antigen; PL7, threonyl-tRNA synthetase; PM75/100, polymyositis-scleroderma (PM/ScI) overlap antigens part of the nucleolar PM/ScI complex; Ro52: tripartite motif 21 antigen; SAE1, component of the small ubiquitin like modifier activating enzyme heterodimer; Scl-70, DNA topoisomerase I; SSA/Ro60, Sjögren syndrome antigen A; SSB, Sjögren syndrome antigen B. For more details on the nomenclature used for the autoimmune assays please refer to the online materials and methods.

Legend: The left panel shows the specific AAB serology of COVID⁺ patients, the right panel shows the specific AAB serology of COVID⁻ patients, and the lower panel shows specific AAB that were detected on only one patient, shown separately for clarity. The titres were classified into low, medium and high levels using cutoffs established by the laboratory, shown in light grey, dark grey and black, respectively; white indicates negative. Arrival indicates the first sample obtained, either on the day of admission or the next morning. Within 10 d indicates during the longitudinal sampling, up to day 10 of ICU stay. After 10 d indicates later samples, collected every two weeks; not all patients had samples after 10 days. The following specific AAB were not detected in any samples: histones, Sm/U2-U6 RNP, U1-RNP, ribosomal P, topoisomerase I, Mi2-α, MDA5, NXP2, PL7, PL12, SRP, EJ, OJ, HMGR or NT5C1 A/Mup44 and SAR1.

Figure 3: Bayesian analysis of the 95% high density credible interval of the difference between COVID⁺ and COVID⁻ levels of autoimmune serology



Abbreviations: AAB, autoantibody; ANA, anti-nuclear antibodies; AAB, autoantibodies; HDI, high density interval; spAAB, antigen-specific autoantibodies.

Legend: A) Posterior distributions of the difference in humoral autoimmunity in COVID⁺ vs. COVID⁻ patients. The histograms plot the difference between the COVID⁺ and COVID⁻ in the proportion of patients who are positive for the variables presented. The 95%HDI is visually represented by the bold black line along the x-axis. The histograms represent simulations using

four Gibbs sampling chains employing a flat prior probability, at 5000 iterations per chain, minus 1% burn-in, resulting in 19800 iterations in total for each histogram. B) Effect of prior bias on posterior distributions. The data was generated using the same procedure as in “A”, with the X axis representing the difference in the posterior distribution between the COVID⁺ and COVID⁻. The flat prior probability was exchanged varying levels of prior bias; the box and whiskers represent the 95% HDI at each level of prior bias. The positive Y axes show the results assuming that COVID⁺ have a higher incidence of positivity than COVID⁻, while the negative Y axes show the opposite; the zero Y indicates a prior that assumes no bias, with an equal probability of 50% positivity rate for both COVID⁺ and COVID⁻. A 95% HDI that does not include the zero on the X axis indicates a significant difference between the COVID⁺ and COVID⁻ posterior probability distributions at that level of prior bias, indicated with a red dot. The simulations were performed on 5% intervals; the results are shown for 10% intervals for clarity.